PDF(Pubmed)
Abstract：
Interleukin 33 (IL-33), once predominantly recognized for its pro-tumoral activities, has emerged as a multifunctional cytokine with antitumor properties. IL-33 pleiotropic activities include activation of Th1 CD4+ T cells, CD8+ T cells, NK cells, dendritic cells, eosinophils, as well as type 2 innate lymphoid cells. Regarding this immunomodulatory activity, IL-33 demonstrates synergistic interactions with various cancer therapies, including immune checkpoint blockade and chemotherapy. Combinatorial treatments leveraging IL-33 exhibit enhanced antitumor efficacy across different tumor models, promising novel avenues for cancer therapy. Despite its antitumor effects, the complex interplay of IL-33 within the tumor microenvironment underscores the need for further investigation. Understanding the mechanisms underlying IL-33\'s dual role as both a promoter and inhibitor of tumor progression is essential for refining therapeutic strategies and fully realizing its potential in cancer immunotherapy. This review delves into the intricate landscape of IL-33 effects within the tumor microenvironment, highlighting its pivotal role in orchestrating immune responses against cancer.
摘要：
白细胞介素33(IL-33),曾经主要因其亲肿瘤活性而被认可，已成为具有抗肿瘤特性的多功能细胞因子。IL-33多效活性包括激活Th1CD4+T细胞，CD8+T细胞，NK细胞,树突状细胞,嗜酸性粒细胞,以及2型先天淋巴细胞。关于这种免疫调节活性，IL-33显示出与各种癌症疗法的协同相互作用，包括免疫检查点阻断和化疗。利用IL-33的组合治疗在不同肿瘤模型中表现出增强的抗肿瘤功效，有希望的癌症治疗新途径。尽管有抗肿瘤作用,IL-33在肿瘤微环境中的复杂相互作用强调了进一步研究的必要性.了解IL-33作为肿瘤进展的启动子和抑制剂的双重作用的潜在机制对于完善治疗策略和充分实现其在癌症免疫治疗中的潜力至关重要。这篇综述深入研究了肿瘤微环境中IL-33效应的复杂景观。强调其在协调针对癌症的免疫反应中的关键作用。
